Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: EC:1.1.1.1 (
alcohol dehydrogenase
)
9,284
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
Dihydrotestosterone (DHT) decreases rat liver
alcohol dehydrogenase
(
ADH
) due principally to an increased rate of degradation of the enzyme. The pathway of degradation of
ADH
was investigated. Exposure of hepatocytes in culture to lactacystin or to MG132, which are inhibitors of the ubiquitin-proteasome pathway of protein degradation, resulted in higher
ADH
. Furthermore, both lactacystin and MG132 prevented the decrease in
ADH
caused by DHT. By contrast, the lysosomal proteolytic inhibitors 3-methyladenine and leupeptin as well as inhibitors of the
calcium-activated neutral protease
calpain system had no effect on
ADH
in the absence or presence of DHT.
ADH
isolated by immunoprecipitation from hepatocytes exposed to DHT reacted specifically with anti-ubiquitin antibody. Ubiquitinated
ADH
was also demonstrated in hepatocytes exposed to MG132. The combination of DHT and MG132 resulted in more ubiquitinated
ADH
than exposure to either compound alone. These results suggest that the ubiquitin-proteasome pathway plays a role in the degradation of
ADH
and in the enhanced degradation of this enzyme by DHT.
...
PMID:Liver alcohol dehydrogenase is degraded by the ubiquitin-proteasome pathway. 1145 41